35932 Federal Register / Vol. 63, No. 126 /Wednesday, July 1, 1998 / Notices

holding company. The factors that are

considered in acting on the notices are

set forth in paragraph 7 of the Act (12

U.S.C. 1817(j)(7)).

The notices are available for

immediate inspection at the Federal

Reserve Bank indicated. The notices

also will be available for inspection at

the offices of the Board of Governors.

Interested persons may express their

views in writing to the Reserve Bank

indicated for that notice or to the offices

of the Board of Governors. Comments

must be received not later than July 17,

1998.

A. Federal Reserve Bank of Atlanta

(Lois Berthaume, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303-2713:

1. Patricia McLaurin Morgan, Richard

Brand Morgan, Paul Mangum Morgan,

all of Lawrenceville, Georgia; to acquire

voting shares of Brand Banking

Company, Lawrenceville, Georgia.

Board of Governors of the Federal Reserve

System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–17454 Filed 6–30–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than July 27, 1998.

A. Federal Reserve Bank of New

York (Betsy Buttrill White, Senior Vice

President) 33 Liberty Street, New York,

New York 10045-0001:

1. CNY Financial Corporation,

Cortland, New York; to become a bank

holding company by acquiring Cortland

Savings Bank, Cortland, New York.

Board of Governors of the Federal Reserve

System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–17455 Filed 6–30–98; 8:45 am]

BILLING CODE 6210–01–F

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. The application also will be

available for inspection at the offices of

the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than July 27, 1998.

A. Federal Reserve Bank of Chicago

(Philip Jackson, Applications Officer)

230 South LaSalle Street, Chicago,

Illinois 60690-1413:

1. Old Kent Financial Corporation,

Grand Rapids, Michigan; to merge with

First Evergreen Corporation, Evergreen

Park, Illinois, and thereby indirectly

acquire First National Bank of Evergreen

Park, Evergreen Park, Illinois.

B. Federal Reserve Bank of St. Louis

(Randall C. Sumner, Vice President) 411

Locust Street, St. Louis, Missouri 63102-

2034:

1. First Banks, Inc., Creve Coeur,

Missouri; and its wholly owned

subsidiary CCB Bancorp, Inc., Newport

Beach, California; to acquire 100 percent

of the voting shares of Republic Bank,

Torrance, California.

Board of Governors of the Federal Reserve

System, June 26, 1998.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 98–17527 Filed 6-30-98; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in

Permissible Nonbanking Activities or

to Acquire Companies that are

Engaged in Permissible Nonbanking

Activities

The companies listed in this notice

have given notice under section 4 of the

Bank Holding Company Act (12 U.S.C.

1843) (BHC Act) and Regulation Y, (12

CFR Part 225) to engage de novo, or to

acquire or control voting securities or

assets of a company, including the

companies listed below, that engages

either directly or through a subsidiary or

other company, in a nonbanking activity

that is listed in § 225.28 of Regulation

Y (12 CFR 225.28) or that the Board has

determined by Order to be closely

related to banking and permissible for

bank holding companies. Unless

otherwise noted, these activities will be

conducted throughout the United States.

Each notice is available for inspection

at the Federal Reserve Bank indicated.

The notice also will be available for

inspection at the offices of the Board of

Governors. Interested persons may

express their views in writing on the

question whether the proposal complies

with the standards of section 4 of the

BHC Act.

Unless otherwise noted, comments

regarding the applications must be

received at the Reserve Bank indicated

or the offices of the Board of Governors

not later than July 17, 1998.

A. Federal Reserve Bank of Boston

(Richard Walker, Community Affairs

Officer) 600 Atlantic Avenue, Boston,

Massachusetts 02106-2204:

1. BankBoston Corporation (BKB),

Boston, Massachusetts; to acquire

Robertson Stephens, Inc., San Francisco,

California, and thereby engage in
Federal Register / Vol. 63, No. 126 /Wednesday, July 1, 1998 / Notices 35933

underwriting and dealing to a limited

extent in all types of equity securities,

other than ownership interest in openend investment companies; making,

acquiring and servicing loans and other

extensions of credit, pursuant to §

225.28(b)(1) of Regulation Y; providing

investment and financial advisory

services, pursuant to § 225.28(b)(6) of

Regulation Y; arranging commercial or

industrial real estate equity financing,

pursuant to § 225.28(b)(2)(ii) of

Regulation Y; underwriting and dealing

in obligations of the United States and

Canada, general obligations of U.S.

States, Canadian provinces, and their

political subdivisions, and other

obligation in which state member banks

may underwrite and deal under 12

U.S.C. 24 and 335, pursuant to §

225.28(b)(8) of Regulation Y; and

providing securities brokerage, private

placement, and riskless principal

services, pursuant to § 225.28(b)(7)(i),

(ii), and (iii) of Regulation Y. The

proposed activities are currently being

conducted, directly or indirectly, by the

subject entities with Board approval.

(See Bank of Boston Corp., 83 Fed. Res.

Bull. 42 (1997) and Bank America Corp.,

83 Fed. Res. Bull. 1008 (1997)).

Board of Governors of the Federal Reserve

System, June 25, 1998.

Robert deV. Frierson,

Associate Secretary of the Board.

[FR Doc. 98–17453 Filed 6–30–98; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct;

Terry D. Reisine, Ph.D.

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made a final finding of scientific

misconduct in the following case:

Terry D. Reisine, Ph.D., University of

Pennsylvania: Based upon ‘‘The Dean’s

Proposed Findings of Fact’’ and

‘‘Memorandum on Issues Not Fully

Addressed in Findings of Fact,’’

forwarded to ORI by the University of

Pennsylvania, dated October 25, 1996

(Findings and Memorandum), and ORI’s

oversight review of the evidence

provided, ORI finds that Terry D.

Reisine, Ph.D., former Professor,

Department of Pharmacology,

University of Pennsylvania, engaged in

scientific misconduct in biomedical

research supported by Public Health

Service (PHS) grants.

Specifically, ORI finds that the

Respondent falsified results related to

the measurement of cyclic AMP in

cultured, transfected cells by falsely

representing in manuscripts and

publications the number of experiments

conducted, and by falsifying and/or

fabricating some of the substantive data

presented in those manuscripts and

publications. Moreover, ORI finds that

the Respondent attempted to falsify data

by directing members of his laboratory

to construct figures and tables with false

values in the preparation of

manuscripts.

Dr. Reisine has entered into a

Voluntary Exclusion Agreement with

ORI. The settlement is not an admission

of liability on the part of the

Respondent, and Dr. Reisine denies

having committed scientific

misconduct. Pursuant to the Agreement,

Dr. Reisine has agreed to the following:

(1) Respondent agreed to exclude

himself voluntarily for a period of three

(3) years beginning on June 11, 1998,

from any contracting or subcontracting

with any agency of the United States

Government, and from eligibility for or

involvement in nonprocurement

transactions (e.g., grants and cooperative

agreements) of the United States

Government as defined in 45 CFR part

76 (Debarment Regulations).

(2) Respondent agreed to exclude

himself voluntarily from serving in any

advisory capacity to PHS including, but

not limited to, service on any PHS

advisory committee, board, and/or peer

review committee, or as a consultant for

a period of three (3) years, beginning on

June 11, 1998.

(3) Within 30 days of the effective

date of the Agreement, Respondent

agreed to submit letters to the following

journals requesting correction of the

corresponding articles. The corrections

are warranted by the following findings

of the Findings and Memorandum:

a. The Journal of Biological Chemistry

Kong, H., Raynor, K., Yasuda, K., Moe, S.T.,

Portoghese, P.S., Bell, G.I., and Reisine,

T. ‘‘A single residue, aspartic acid 95, in

the gamma opioid receptor specifies

selective high affinity agonist binding.’’

J. Biol. Chem. 268:23055–23058, 1993.

i. The results in Table 1 are stated in the

table legend to be based on four (4)

experiments with calculated SEM values and

Hill coefficients when, in fact, the majority

of the listed compounds were tested only

once, and a few tested only twice.

ii. Figure 2 data are stated in the figure

legend to be the means of three (3) different

experiments when, in fact, most of the results

were based on a single experiment.

b. The Journal of Pharmacology and

Experimental Therapeutics

Raynor, K., Kong, H., Hines, J., Kong, G.,

Benevoc, J., Yasuda, K., Bell, G.I., and

Reisine, T. ‘‘Molecular mechanisms of

agonist-induced desensitization of the

cloned mouse kappa opioid receptor.’’ J.

Pharmacol. Exp. Ther. 270:1381–1386,

1994.

i. The figure legend for Figures 3A, 3C, and

3D claimed that the values shown were the

average of three (3) different experiments

when, in fact, the results were from only one

(1) experiment.

ii. The figure legend for Figure 4B claimed

that the values shown were the average of

four (4) different experiments when, in fact,

the results were from only three (3)

experiments.

iii. Figures 3A, 3C, and 3D each show

several levels of adenyl cyclase inhibition

that do not reflect the actual results obtained

in duplicate cyclic AMP assays.

c. Molecular Pharmacology

Reisine, T., Kong, H., Raynor, K., Yano, H.,

Takeda, J., Yasuda, K., and Bell, G.I.

‘‘Splice variant of the somatostatin

receptor 2 subtype, somatostatin receptor

2B, couples to adenylyl cyclase.’’ Mol.

Pharmacol. 44:1016–1020, 1994.

i. The legend for Figure 3A claims that

three (3) experiments were performed when,

in fact, only two (2) experiments were

performed for the SSTR2B mutants.

ii. The legend for Figure 3B claims that the

values presented are the average of two (2)

different experiments when, in fact, the

inhibition curve shown was based on a single

experiment.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Dorothy K. Macfarlane,

Acting Director, Office of Research Integrity.

[FR Doc. 98–17411 Filed 6–30–98; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Agency for Toxic Substances and

Disease Registry

[Program Announcement 98095]

Enhancement of Local Public Health

Departments Participation in

Brownfields Decisions and Actions;

Notice of Availability of Funds

Introduction

The Agency for Toxic Substances and

Disease Registry (ATSDR) announces

the availability of fiscal year (FY) 1998

funds for a cooperative agreement

program for a pilot activity with a select

number of local health departments to

demonstrate effective public health